Full Press Release Details
ATEC Reports Second Quarter Financial Results and Recent Corporate Highlights
Organic revenue growth accelerates to 93%
Revenue 2-year CAGR of 46%
Full year 2021 total revenue now expected to grow ~64% to ~$238 million
CARLSBAD, Calif., August 3, 2021 - Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2021, and recent corporate highlights.
Second Quarter 2021 Financial Results
| Quarter Ended | |
| June 30, 2021 | |
| Total revenue | $62.2 million |
| GAAP gross margin | 66.0% |
| Non-GAAP gross margin | 73.2% |
| Operating expenses | $76.8 million |
| Non-GAAP operating expenses | $57.2 million |
| GAAP operating loss | ($35.8) million |
| Non-GAAP adjusted EBITDA | ($6.6) million |
| Ending cash balance | $76.6 million |
"We are accelerating revenue through sound execution of our growth priorities," said Pat Miles, Chairman and Chief Executive Officer. "But this is just the first inning; we intend to become the dominant force in the industry by significantly improving the clinical experience in spine. We channeled decades of spine experience as the pioneers of lateral surgery to create the PTP technique in order to improve the optionality and predictability of the lateral approach. PTP adoption is accelerating and utilization is increasing among both new and existing surgeon customers. In a few short years, we have created surgical approaches and products that are unrivaled. With the close of the EOS transaction, we intend to extend our prowess by equipping the AlphaInformatiX platform with unprecedented imaging information throughout the entire
continuum of care, bringing the standards relied on by the world's most prestigious academic centers to spine surgery. Our early success has driven excitement within these walls that is palpable - we know the opportunity ahead of us and are confident we have what it takes to win in the innings ahead."
Financial Outlook for the Full Year 2021
The Company now expects total revenue for the fiscal year ended December 31, 2021, to approximate $238 million, reflecting growth of approximately 64% compared to the prior full year. This includes an organic revenue contribution of approximately $212 million, or 50% growth compared to the prior full year. The Company anticipates about $25 million of revenue related to EOS imaging. Total revenue guidance for the full year 2021 also includes a $1 million contribution from the Company's international supply agreement, which will terminate on August 31, 2021.
Investor Conference Call
ATEC will present these results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast can be accessed by visiting the Investor Relations section of ATEC's Corporate Website at investors.alphatecspine.com/quarterly-results. Participants should go to the website at least 15 minutes before the event to register, and download and install any necessary software.
To dial-in to the webcast, registration may be completed by visiting the following registration link: http://www.directeventreg.com/registration/event/4976259. Once registered, each dial-in participant will be provided access details and a registrant ID.
A replay of the webcast will remain available through the Investor Relations section of ATEC's Corporate Website at investors.alphatecspine.com/quarterly-results for twelve months. In addition, a replay of the audiocast will be available beginning two hours after the call's completion until August 10, 2021. The replay dial-in numbers are (800)585-8367 for domestic callers and (416)621-4642 for international callers. Please use the replay conference ID number 4976259.
Non-GAAP Financial Information
To supplement the Company's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP U.S. gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP Adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-
recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.
About Alphatec Holdings, Inc.
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company's expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; the Company's future ability to finance its operations and sufficiency of its cash runway; and statements about the potential benefits and synergies of the acquisition of EOS imaging, S.A. (including expected impact on future financial and operating results and post-acquisition plans and intentions). Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; the Company's ability to meet its financial
obligations; the impact of the COVID-19 pandemic on the Company and economy; and uncertainties and risks related to the integration of EOS imaging, S.A. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
Investor/Media Contact:
Chief Financial Officer
ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| unaudited | |||||||||||||||
| Revenues: | |||||||||||||||
| Revenue from products and services | $ | 61,885 | $ | 28,834 | $ | 105,601 | $ | 57,904 | |||||||
| Revenue from international supply agreement | 364 | 795 | 769 | 1,840 | |||||||||||
| Total revenues | 62,249 | 29,629 | 106,370 | 59,744 | |||||||||||
| Cost of revenues | 21,184 | 8,787 | 33,447 | 17,871 | |||||||||||
| Gross profit | 41,065 | 20,842 | 72,923 | 41,873 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 7,839 | 4,237 | 13,640 | 8,406 | |||||||||||
| Sales, general and administrative | 60,659 | 26,468 | 101,085 | 54,051 | |||||||||||
| Litigation-related | 1,167 | 1,304 | 4,502 | 3,947 | |||||||||||
| Amortization of acquired intangible assets | 1,208 | 172 | 1,380 | 344 | |||||||||||
| Transaction-related | 4,771 | (181 | ) | 5,783 | 4,091 | ||||||||||
| Restructuring | 1,173 | - | 1,331 | - | |||||||||||
| Total operating expenses | 76,817 | 32,000 | 127,721 | 70,839 | |||||||||||
| Operating loss | (35,752 | ) | (11,158 | ) | (54,798 | ) | (28,966 | ) | |||||||
| Interest and other expense, net: | |||||||||||||||
| Interest expense, net | (2,394 | ) | (3,032 | ) | (4,332 | ) | (5,906 | ) | |||||||
| Other expenses | (16 | ) | (1,555 | ) | (1,905 | ) | (1,555 | ) | |||||||
| Total interest and other expenses, net | (2,410 | ) | (4,587 | ) | (6,237 | ) | (7,461 | ) | |||||||
| Loss from continuing operations before taxes | (38,162 | ) | (15,745 | ) | (61,035 | ) | (36,427 | ) | |||||||
| Income tax provision | 43 | 60 | 73 | 100 | |||||||||||
| Net loss | $ | (38,205 | ) | $ | (15,805 | ) | $ | (61,108 | ) | $ | (36,527 | ) | |||
| Net loss per share, basic and diluted | $ | (0.39 | ) | $ | (0.25 | ) | $ | (0.66 | ) | $ | (0.58 | ) | |||
| Shares used in calculating basic and diluted net loss per share | 98,541 | 63,713 | 92,912 | 63,140 | |||||||||||
| Stock-based compensation included in: | |||||||||||||||
| Cost of revenues | $ | 235 | $ | 128 | $ | 330 | $ | 235 | |||||||
| Research and development | 664 | 563 | 1,162 | 954 | |||||||||||
| Sales, general and administrative | 10,597 | 3,884 | 14,478 | 6,954 | |||||||||||
| $ | 11,496 | $ | 4,575 | $ | 15,970 | $ | 8,143 |
ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2021 | December 31, 2020 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 76,581 | $ | 107,765 | ||||
| Accounts receivable, net | 33,743 | 23,527 | ||||||
| Inventories, net | 86,715 | 46,001 | ||||||
| Prepaid expenses and other current assets | 8,108 | 5,439 | ||||||
| Withholding tax receivable from Officer | 1,076 | 1,076 | ||||||
| Current assets of discontinued operations | 136 | 352 | ||||||
| Total current assets | 206,359 | 184,160 | ||||||
| Property and equipment, net | 66,051 | 36,670 | ||||||
| Right-of-use asset | 26,604 | 1,177 | ||||||
| Goodwill | 45,189 | 13,897 | ||||||
| Intangible assets, net | 92,981 | 24,720 | ||||||
| Other assets | 3,786 | 541 | ||||||
| Noncurrent assets of discontinued operations | 57 | 58 | ||||||
| Total assets | $ | 441,027 | $ | 261,223 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 29,812 | $ | 17,599 | ||||
| Accrued expenses and other current liabilities | 43,455 | 35,264 | ||||||
| Contract liability | 20,392 | - | ||||||
| Short-term debt | 10,988 | 4,167 | ||||||
| Current portion of operating lease liability | 2,777 | 885 | ||||||
| Current liabilities of discontinued operations | 141 | 397 | ||||||
| Total current liabilities | 107,565 | 58,312 | ||||||
| Total long term liabilities | 96,345 | 49,428 | ||||||
| Redeemable preferred stock | 23,603 | 23,603 | ||||||
| Stockholders' equity | 213,514 | 129,880 | ||||||
| Total liabilities and stockholders' equity | $ | 441,027 | $ | 261,223 |
ALPHATEC HOLDINGS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| unaudited | ||||||||||||||||
| Gross profit, GAAP | $ | 41,065 | $ | 20,842 | $ | 72,923 | $ | 41,873 | ||||||||
| Add: amortization of intangible assets | 268 | 268 | 536 | 536 | ||||||||||||
| Add: stock-based compensation | 235 | 128 | 330 | 235 | ||||||||||||
| Add: Purchase accounting adjustments on acquisitions | 1,763 | - | 1,763 | - | ||||||||||||
| Add: non-cash excess and obsolete charges | 2,221 | 1,712 | 4,317 | 3,434 | ||||||||||||
| Non-GAAP gross profit | $ | 45,552 | $ | 22,950 | $ | 79,869 | $ | 46,078 | ||||||||
| Gross margin, GAAP | 66.0 | % | 70.3 | % | 68.6 | % | 70.1 | % | ||||||||
| Add: amortization of intangible assets | 0.4 | % | 0.9 | % | 0.5 | % | 0.9 | % | ||||||||
| Add: stock-based compensation | 0.4 | % | 0.4 | % | 0.3 | % | 0.4 | % | ||||||||
| Add: Purchase accounting adjustments on acquisitions | 2.8 | % | - | % | 1.7 | % | - | % | ||||||||
| Add: non-cash excess and obsolete charges | 3.6 | % | 5.8 | % | 4.1 | % | 5.7 | % | ||||||||
| Non-GAAP gross margin | 73.2 | % | 77.5 | % | 75.1 | % | 77.1 | % | ||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| unaudited | ||||||||||||||||
| Operating expenses, GAAP | $ | 76,817 | $ | 32,000 | $ | 127,721 | $ | 70,839 | ||||||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation | (11,261 | ) | (4,447 | ) | (15,640 | ) | (7,908 | ) | ||||||||
| Litigation-related expenses | (1,167 | ) | (1,304 | ) | (4,502 | ) | (3,947 | ) | ||||||||
| Amortization of intangible assets | (1,208 | ) | (172 | ) | (1,380 | ) | (344 | ) | ||||||||
| Transaction-related expenses | (4,771 | ) | 181 | (5,783 | ) | (4,091 | ) | |||||||||
| Restructuring expenses | (1,173 | ) | - | (1,331 | ) | - | ||||||||||
| Non-GAAP operating expenses | $ | 57,237 | $ | 26,258 | $ | 99,085 | $ | 54,549 | ||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| unaudited | ||||||||||||||||
| Operating loss, GAAP | $ | (35,752 | ) | $ | (11,158 | ) | $ | (54,798 | ) | $ | (28,966 | ) | ||||
| Depreciation | 5,068 | 2,161 | 8,477 | 4,175 | ||||||||||||
| Amortization of intangible assets | 1,476 | 441 | 1,917 | 881 | ||||||||||||
| EBITDA | (29,208 | ) | (8,556 | ) | (44,404 | ) | (23,910 | ) | ||||||||
| Add back significant items: | ||||||||||||||||
| Stock-based compensation | 11,496 | 4,575 | 15,970 | 8,143 | ||||||||||||
| Purchase accounting adjustments on acquisitions | 1,763 | - | 1,763 | - | ||||||||||||
| Excess & obsolete charges | 2,221 | 1,712 | 4,317 | 3,434 | ||||||||||||
| Litigation-related expenses | 1,167 | 1,304 | 4,502 | 3,947 | ||||||||||||
| Transaction-related expenses | 4,771 | (181 | ) | 5,783 | 4,091 | |||||||||||
| Restructuring expenses | 1,173 | - | 1,331 | - | ||||||||||||
| Adjusted EBITDA | $ | (6,617 | ) | $ | (1,146 | ) | $ | (10,738 | ) | $ | (4,295 | ) |